FOI release

FOI request RMPs Topamax

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2025/01053

Received 29 September 2025

Published 5 November 2025

Request

I would be grateful if you could provide teh RMPs as suggested in your letter i.e. brand leader Topamax (PL 00242/0303) instead of Topiramate, and Revlimid (PLGB 15105/0116-0122) instead of Lenalidomide Tablets.

Response

See attached

Documents

• Apixaban FC Tablets PL 43542 0203-0204 RMP_Redacted (redacted).pdf (7.9 MB)
• FOI2025_01053 Response (redacted).pdf (671.5 KB)
• Topamax PL 00242 0301-0304 RMP_Redacted (redacted).pdf (8.1 MB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.